Dr. Chun-Hao Huang is Co-Founder and CEO of Algen. He is a genetic engineer and drug developer. Dr. Huang received his postdoctoral fellow at UC Berkeley under Nobel Laureate Professor Jennifer Doudna, and his PhD at MSKCC under HHMI Professor Scott Lowe. He pioneered disease-relevant models using CRISPR, which led to the discovery of new therapeutic strategies for treating cancer and inflammatory diseases. He also applied ML to the study of gene functions and invented methods to identify biomarkers that predict drug responses. Dr. Huang is the Lindau Nobel Laureate Meeting Fellow, UN’s UNLEASH Sustainable Development Goals Talent, and Innovators Under 35. He has authored over 10 patents, 40 scientific papers, and 4,000 citations across top-tier journals.